东北证券指出，2026年有望成为中国医疗器械板块的价值重构年。政策压力并非行业的终点：外有投资 回收期缩短、医院现金流改善促进采购决策，叠加医保/DRG政策优化预期；内有倒逼厂商创新+出海双 线并行；有望开启创新技术加速兑现、全球影响力持续提升的新发展阶段。当前，板块基本面已现拐 点，但机构持仓却处于近年历史低位，或可关注预期差下的投资机遇。 12月25日午后，三大指数集体拉升，白酒、医疗器械等多个低位板块走强。医疗器械指数ETF （159898）盘中上涨1.29%，据iFind数据，盘中该ETF申购3600万份。成分股方面，赛诺医疗涨超 14%，麦澜德涨超11%，伟思医疗、硕世生物等涨超7%，迈瑞医疗、联影医疗、奕瑞科技等多个权重股 走强。 消息面上，第六批国家高价值耗材集采启动，引入多重机制防止恶意低价。据智通财经12月23日报道， 新一批国家组织高值医用耗材集采正式启动，将对药物涂层球囊类、泌尿介入类医用耗材进行集采，于 2026年1月13日开标。与前五轮高值医用耗材的集中采购不同，此轮集采有两个新亮点：一是引入了锚 点价格的概念，二是引入了多重复活机制。 此外，据中国证券报，12月25日，国家药监局《 ...

产业链来看，医疗器械是指直接或间接用于人体的仪器、设备、器具、体外诊断试剂及校准物、材料等，其上游涵盖原材料供应、核心零部件制造与研发设 计服务等基础保障，中游是产业链的核心引擎，涵盖产品研发、生产制造、注册认证、流通分销等环节，均具有高壁垒特征。 目前医疗器械指数ETF（159898）跟踪中证全指医疗器械，标的指数细分行业主要分布在医疗设备、医疗耗材、体外诊断等板块，重仓迈瑞、联影、奕瑞科 技等细分龙头，百分之百聚焦A股医疗器械，β质地纯粹，或可更好把握板块整体机遇。 从市值占比上来看，该指数创业板+科创板合计占比超80%，科技成长特性亦较为突出。 | 医疗器械指数ETF159898 2 | | | +1.10% 20日 +0.00% | | --- | --- | --- | --- | | | | | 60日 -7.24% 120日 +5.15% | | 0. 551 +0.008 +1.473% | | | 年初至今+5.76% 250日 +1.47% 52周島高 0 551 52周島任 0 542 | | 委比 +41.06% 94567 | | ੜ੍ਹ ਸਿ | 甲阿 15-0 | | 5 | 0 ...

| 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 3.30 | 338.61 | 102.61 | 0.00 | 中信证券股份有限公司 | 中信建投证券股份有限公司 | | | | | | 总部(非营业场所) | 北京望京证券营业部 | 进一步统计，近3个月内该股累计发生4笔大宗交易，合计成交金额为3.70亿元。 （文章来源：证券时报网） 证券时报·数据宝统计显示，奕瑞科技今日收盘价为102.61元，下跌1.51%，日换手率为2.76%，成交额 为5.56亿元，全天主力资金净流入5324.82万元，近5日该股累计上涨5.33%，近5日资金合计净流入 7634.54万元。 两融数据显示，该股最新融资余额为7.16亿元，近5日增加331.98万元，增幅为0.47%。（数据宝） 奕瑞科技12月24日大宗交易平台出现一笔成交，成交量3.30万股，成交金额338.61万元，大宗交易成交 价为102 ...

Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

重要声明 本报告依据《公司债券发行与交易管理办法》《关于上海奕瑞光电子科技股 份有限公司向不特定对象发行可转换公司债券之债券受托管理协议》（以下简称 "《受托管理协议》"）《上海奕瑞光电子科技股份有限公司向不特定对象发行 可转换公司债券募集说明书》（以下简称"《募集说明书》"）等相关规定，由 本次债券受托管理人中国国际金融股份有限公司（以下简称"中金公司"）编制。 中金公司对本报告中所包含的从上述文件中引述内容和信息未进行独立验证，也 不就该等引述内容和信息的真实性、准确性和完整性做出任何保证或承担任何责 任。 股票代码：688301 股票简称：奕瑞科技 债券代码：118025 债券简称：奕瑞转债 奕瑞电子科技集团股份有限公司 向不特定对象发行可转换公司债券 第五次临时受托管理事务报告 （2025 年度） 债券受托管理人 二〇二五年十二月 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中金公司所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，中金公 司不承担任何责任。 1 中国国际金融股份有限公司作为奕瑞电子科 ...

奕瑞科技公告称，公司已完成2021年限制性股票激励计划预留授予部分第三个归属期的归属登记手续， 总股本由2.114117亿股增加至2.11449139亿股。"奕瑞转债"转股价格相应调整为114.97元/股，自2025年 12月22日起生效。"奕瑞转债"于12月19日停止转股，12月22日起恢复转股。该债券发行规模14.35亿 元，期限为2022年10月24日至2028年10月23日。 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-111 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 12 月 17 日 召开第三届董事会第二十二次会议，审议通过《关于以集中竞价交易方式回购公 司股份方案的议案》，并于 2025 年 12 月 18 日披露了《奕瑞科技关于以集中竞价 交易方式回购公司股份的回购报告书》（公告编号：2025-101）、《奕瑞科技第三 届董事会第二十二次会议决议公告》（公告编号：2025-100）。 二、公司前十名无限售条件股东持股情况 | 序号 | 股东名称 | 总持有数量 | 占无限售条件流 | | --- | --- | --- | --- | | | | （股） | 通股比例（%） | | 1 | 上海奕原禾锐投资咨询有限公司 | 29,452,682 | 14.70 | | 2 | 海南合毅投资有限公司 | 11,721,318 | 5.85 | | 3 | 上海常则管理咨询合伙企业（有限合伙 ...

Group 1 - The core viewpoint of the news is that Yirui Technology's stock has experienced fluctuations, with a current price of 104.52 CNY per share and a market capitalization of 22.097 billion CNY, reflecting a year-to-date increase of 54.67% [1] - As of September 30, 2025, Yirui Technology reported a revenue of 1.549 billion CNY, representing a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 471 million CNY, which is a 20.61% increase compared to the previous year [2] - The company has distributed a total of 789 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3] Group 2 - Yirui Technology's main business involves the research, production, sales, and service of digital X-ray detectors, with the sales of detectors accounting for 81.21% of its main revenue [1] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices, and is involved in sectors such as in vitro diagnostics and precision medicine [1] - As of September 30, 2025, the number of shareholders increased by 14.61% to 8,011, while the average circulating shares per person decreased by 12.74% to 24,992 shares [2]

Group 1 - The medical device sector increased by 0.56% on December 19, with Kangzhong Medical leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] - Notable gainers in the medical device sector included Kangzhong Medical, which rose by 7.36% to a closing price of 44.90, and Rendu Biotech, which increased by 6.78% to 50.40 [1] Group 2 - The medical device sector experienced a net inflow of 3.65 million yuan from institutional investors, while retail investors saw a net inflow of 15 million yuan [2] - Major stocks with significant net inflows included Rejing Bio with 49.71 million yuan and Yuyue Medical with 43.84 million yuan [3] - Conversely, retail investors showed net outflows in several stocks, including Yuyue Medical and Mairui Medical, indicating a mixed sentiment in the market [3]

Group 1 - The core viewpoint of the news is that Yirui Technology's stock has seen a significant increase of 5.02%, reaching a price of 106.66 yuan per share, with a total market capitalization of 22.549 billion yuan [1] - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, specializes in the research, production, sales, and services of digital X-ray detectors [1] - The main revenue composition of Yirui Technology includes 81.21% from detector sales, 7.66% from core component sales, 5.89% from solutions/technical services, 4.57% from accessory sales, and 0.66% from leasing income [1] Group 2 - From the perspective of fund holdings, one fund under Taikang Asset Management has Yirui Technology as a significant investment, holding 41,500 shares, which accounts for 3.99% of the fund's net value, ranking it as the seventh largest holding [2] - The Taikang Medical Health Stock Fund A (015139) was established on March 8, 2022, with a current scale of 76.9785 million yuan, and has experienced a year-to-date loss of 12.75% [2] - The fund manager, Fu Hongzhe, has been in position for nearly 3 years, with the fund's total assets amounting to 311 million yuan, and the best and worst returns during his tenure being 4.69% and -10.79%, respectively [3]